PREVENTION OF
PREECLAMPSIA
ROLE OF ASPIRIN AND CALCIUM
Dr Kanddy
O&G Updates
Miri Hospital
1/11/14
DEFINITIONS
• Chronic hypertension
• Hypertension (BP ≫
140
90
mmHg; 4 – 6 hours apart); < 20 weeks of gestation
• G...
• Eclampsia
• Seizure associated with pre-eclampsia
• Chronic hypertension with superimposed pre-eclampsia
• Unclassifi...
PATHOPHYSIOLOGY
• Unknown
BURDEN OF PRE-ECLAMPSIA
• One of the major cause of
maternal mortality
MATERNAL MORTALITY - MALAYSIA
• Fetal/neonatal morbidity/mortality
• 1 in 20 (5%) stillbirths occurred in women with pre-eclampsia
• 8 – 10% of all pr...
REDUCING THE RISK OF HYPERTENSIVE
DISORDERS IN PREGNANCY
• Pre-existing risk factors
• Modifiable
• Obesity
• Non-mod...
ANTIPLATELET AGENTS
• Rational
• Pre-eclampsia is associated with deficient intravascular production of
prostacyclin (a...
CLASP TRIAL
• Multicentre study
• 9364 women – randomly assigned 60 mg aspirin or matching placebo
• 74% entered for prophylaxis of ...
• Was not associated with a significant increase in placental haemorrhages or
bleeding during epidural anaesthesia
• Saf...
• All randomised trials comparing antiplatelet agents with either placebo or no
antiplatelet agent were included
• To as...
• Significant increase in the absolute risk reduction of pre-elampsia for high risk
compared with moderate risk women
• ...
RECOMMENDATION
• Advice women at high of pre-eclampsia to take 75 mg of aspirin daily from
12 weeks until birth of baby ...
• Moderate risk (more than one of the following)
• First pregnancy
• Age 40 year-old
• Pregnancy interval of more than ...
ROLE OF CALCIUM
• To assess the effects of calcium supplementation during pregnancy on
hypertensive disorders of pregnancy and related ma...
• Effect was greatest for women with low baseline calcium intake (RR 0.36) and
those high risk
• Risk of preterm birth r...
LIMITATION OF
RECOMMENDATION
• Benefits are greatest in women with deficient dietary calcium
• Is it relevant to our po...
OTHER INTERVENTIONS
• Not recommended
• Rest
• Low salt diet
• Exercise in pregnancy
• Weight management in pregnancy...
THANK YOU
ANY QUESTIONS?????
Prevention of pre-eclampsia
Prevention of pre-eclampsia
of 24

Prevention of pre-eclampsia

Prevention of Pre-eclampsia
Published on: Mar 4, 2016
Published in: Health & Medicine      
Source: www.slideshare.net


Transcripts - Prevention of pre-eclampsia

  • 1. PREVENTION OF PREECLAMPSIA ROLE OF ASPIRIN AND CALCIUM Dr Kanddy O&G Updates Miri Hospital 1/11/14
  • 2. DEFINITIONS • Chronic hypertension • Hypertension (BP ≫ 140 90 mmHg; 4 – 6 hours apart); < 20 weeks of gestation • Gestational hypertension • Hypertension (BP ≫ 140 90 mmHg; 4 – 6 hours apart); > 20 weeks of gestation • Without significant proteinuria • Pre – eclampsia • Hypertension (BP ≫ 140 90 mmHg; 4 – 6 hours apart); > 20 weeks of gestation • With significant proteinuria – urine dipstick 2+ or more; or 24 hours urine protein 300 mg per day or more
  • 3. • Eclampsia • Seizure associated with pre-eclampsia • Chronic hypertension with superimposed pre-eclampsia • Unclassified hypertension • Hypertension (BP ≫ 140 90 mmHg; 4 – 6 hours apart); > 20 weeks of gestation but no BP record prior to that Based on ISSHP 2001 (International Society for Study of Hypertension in Pregnancy)
  • 4. PATHOPHYSIOLOGY • Unknown
  • 5. BURDEN OF PRE-ECLAMPSIA • One of the major cause of maternal mortality
  • 6. MATERNAL MORTALITY - MALAYSIA
  • 7. • Fetal/neonatal morbidity/mortality • 1 in 20 (5%) stillbirths occurred in women with pre-eclampsia • 8 – 10% of all preterm birth result from hypertensive disorders • Small for gestational age
  • 8. REDUCING THE RISK OF HYPERTENSIVE DISORDERS IN PREGNANCY • Pre-existing risk factors • Modifiable • Obesity • Non-modifiable • Medical illnesses • Age • Primiparity • Family history
  • 9. ANTIPLATELET AGENTS • Rational • Pre-eclampsia is associated with deficient intravascular production of prostacyclin (a vasodilator) and excessive production of thromboxane – a vasoconstrictor and stimulant of platelet aggregation • Antiplatelet agents – might prevent or delay development of pre-eclampsia • Evidence • Before CLASP TRIAL • Small trials of antiplatelet therapy • Reduction of about three-quarters in the incidence of PE • Some avoidance of IUGR
  • 10. CLASP TRIAL
  • 11. • Multicentre study • 9364 women – randomly assigned 60 mg aspirin or matching placebo • 74% entered for prophylaxis of pre-eclampsia • 12% for prophylaxis of IUGR • 3% for treatment of IUGR • Results • Use of aspirin was associated with a reduction of only 12% in the incidence of proteinuric pre-eclampsia (not significant) • No significant effect on the incidence of IUGR or stillbirth and neonatal death • Significantly reduce the likelihood of premature delivery (19.7% vs 22,2%; p=0.004)
  • 12. • Was not associated with a significant increase in placental haemorrhages or bleeding during epidural anaesthesia • Safe for the fetus and newborn infant • Conclusion • Do not support routine prophylactic or therapeutic administration of antiplatelet therapy in pregnancy to all women at increased risk of pre-eclampsia or IUGR • May be justified in women judged to be especially liable to early onset PE severe enough to need very preterm delivery
  • 13. • All randomised trials comparing antiplatelet agents with either placebo or no antiplatelet agent were included • To assess the effectiveness and safety of antiplatelet agents for women at risk of developing pre-eclampsia • Participants were pregnant women at risk of developing pre-eclampsia • Results • 59 trials (37,560 women) included • 17% reduction in the risk of pre-eclampsia associated with the use of antiplatelet agents; RR 0.83; NNT 72 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systemic Reviews 2007.
  • 14. • Significant increase in the absolute risk reduction of pre-elampsia for high risk compared with moderate risk women • 8% reduction in relative risk of preterm birth; NNT 72 • 14% reduction in fetal or neonatal death • 10% reduction in small-for-gestational age babies • Conclusion • Antiplatelet agents have moderate benefits when used for prevention of pre-eclampsia and its consequences Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systemic Reviews 2007.
  • 15. RECOMMENDATION • Advice women at high of pre-eclampsia to take 75 mg of aspirin daily from 12 weeks until birth of baby • High risk factors (any one of the following) • Hypertensive disease during a previous pregnancy • Chronic kidney disease • Autoimmune disease such as SLE or antiphospholipid syndrome • Type 1 or 2 DM • Chronic hypertension NICE Clinical Guideline; Hypertension in Pregnancy; August 2010 (revised reprint January 2011)
  • 16. • Moderate risk (more than one of the following) • First pregnancy • Age 40 year-old • Pregnancy interval of more than 10 years • BMI of 35 or more at first visit • Family history of pre-eclampsia • Multiple pregnancy NICE Clinical Guideline; Hypertension in Pregnancy; August 2010 (revised reprint January 2011)
  • 17. ROLE OF CALCIUM
  • 18. • To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child outcomes • Randomised trials comparing at least 1 g daily of calcium during pregnancy with placebos • Results • 13 studies; 15730 women • The average risk of high blood pressure was reduced with calcium supplementation (RR 0.65) • Reduction in the average risk of pre-eclampsia associated with calcium (RR 0.45)
  • 19. • Effect was greatest for women with low baseline calcium intake (RR 0.36) and those high risk • Risk of preterm birth reduced (RR 0.76) • Composite outcome maternal death or serious morbidity was reduced (RR 0.80) • No overall effect on the risk of stillbirth or death • Anomalous increase in the risk of HELLP syndrome (RR 2.67) • Subgroup analysis showed no statistically significant effect of calcium on the incidence of pre-eclampsia in women with adequate dietary calcium
  • 20. LIMITATION OF RECOMMENDATION • Benefits are greatest in women with deficient dietary calcium • Is it relevant to our population? • Significance of the effect is influenced by pre-eclampsia risk status • Greatest benefits for women who are high risk for pre-eclampsia • Large studies were conducted in women at low risk and small trials were conducted in women at high risk • Conclusion • Although large studies on the use of calcium to prevent hypertensive disorders have been carried out, the variation in population and calcium status has made it impossible to reach a conclusion on the value of such treatment
  • 21. OTHER INTERVENTIONS • Not recommended • Rest • Low salt diet • Exercise in pregnancy • Weight management in pregnancy • Other pharmaceutical agents (nitric oxide donors, progesterone, diuretics, LMWH) • Nutritional supplements (Mg, Folic acid, antioxidants, garlic)
  • 22. THANK YOU ANY QUESTIONS?????

Related Documents